BG Pulse Journal USA
ISSN:1947-2536 http://www.bgpulseusa.com/index.php/bg
BG PULSE JOURNAL

UDC: 618.146-006.6-07-084:616-073.43

EFFICIENCY OF SCREENING METHODS IN THE EARLY DETECTION OF BACKGROUND AND PRECANCEROUS DISEASES OF THE CERVIX

Toshboyeva Shohista Chorshanbi qizi
Allamurotova Fotima Tohir qizi
Axtamova Nilufar Akbarjanovna
Samarkand State Medical University, Samarkand, Uzbekistan
https://doi.org/10.5281/zenodo.20391573

Annotation

Background: Cervical cancer remains a leading cause of oncological mortality among women globally, despite being one of the most preventable cancers. Its prevention relies entirely on the early detection and management of background (benign) and precancerous (cervical intraepithelial neoplasia - CIN) lesions. The transition from traditional cytological screening to modern molecular co-testing has fundamentally altered secondary prevention strategies.

Aim: This clinical study aims to evaluate and compare the diagnostic efficiency, sensitivity, and specificity of modern screening modalities (Liquid-Based Cytology combined with High-Risk HPV DNA testing) against traditional conventional Pap smears in detecting early cervical pathologies.

Materials and Methods: A prospective clinical investigation was conducted, finalizing its diagnostic and analytical phase on March 28, 2026. The study encompassed a controlled cohort of 80 female patients of reproductive and early menopausal age with a history of cervical ectopy or chronic cervicitis. The 80 patients were evenly divided: a Modern Screening Group (n=40) utilizing primary HPV DNA co-testing with Liquid-Based Cytology (LBC) and digital colposcopy, and a Control Group (n=40) screened using the traditional Conventional Pap Smear alone.

Results: The comprehensive diagnostic evaluation revealed that the modern co-testing protocol achieved a diagnostic sensitivity of 95.0% and identified high-grade precancerous lesions (CIN II/III) in 17.5% of cases that were largely missed or underestimated by traditional cytology. The Control Group exhibited a false-negative rate of 30.0%, significantly delaying potentially life-saving interventions.

Conclusion: Relying solely on conventional Pap smears is clinically insufficient for the reliable early detection of cervical precancer. Implementing a modern co-testing paradigm—integrating HPV DNA molecular testing with LBC—drastically minimizes false negatives, allows for the precise stratification of oncological risk, and serves as the most highly efficient strategy for eradicating cervical cancer.

Keywords: cervical screening, precancerous diseases, background lesions, Human Papillomavirus (HPV) DNA testing, Liquid-Based Cytology (LBC), Cervical Intraepithelial Neoplasia (CIN), colposcopy, false negatives.

Introduction

The Pathogenesis of Cervical Neoplasia

The development of cervical cancer is a well-documented, slowly progressing continuum that begins with benign background diseases and advances through increasingly severe stages of

precancerous dysplasia. Background diseases of the cervix, such as simple ectopy, leukoplakia without atypia, and chronic cervicitis, do not inherently possess malignant potential but create a compromised mucosal environment susceptible to viral integration [1]. The undisputed primary etiological driver for the transition from a background lesion to a precancerous state—specifically Cervical Intraepithelial Neoplasia (CIN)—is persistent infection with high-risk genotypes of the Human Papillomavirus (hrHPV), most notably strains 16 and 18 [2].

When the local immune system fails to clear the virus, HPV DNA integrates into the host genome of the cervical transformation zone. This integration triggers the overexpression of viral oncoproteins E6 and E7, which subsequently bind and inactivate the host's critical tumor suppressor genes, p53 and the retinoblastoma protein (pRb) [3]. This molecular sabotage deregulates the cell cycle, leading to the unchecked cellular proliferation characteristic of CIN and, ultimately, invasive squamous cell carcinoma.

The Evolution of Screening Paradigms

Because the progression from initial HPV infection to invasive cancer typically spans 10 to 15 years, cervical cancer is uniquely suited for secondary prevention through mass screening. For decades, the cornerstone of this effort was the Conventional Papanicolaou (Pap) smear [4]. While the conventional Pap smear historically reduced cervical cancer incidence, it is severely limited by poor sample quality, obscuring blood or mucus, and subjective microscopic interpretation, resulting in a dangerously high false-negative rate ranging from 20% to 50% [5].

Modern gynecological oncology has initiated a paradigm shift to mitigate these limitations. Liquid-Based Cytology (LBC) was developed to eliminate obscuring artifacts, providing a clean monolayer of cells for the cytopathologist [6]. More importantly, the integration of molecular HPV DNA testing (co-testing) allows clinicians to detect the specific viral trigger long before morphologic cellular changes occur [7]. This study rigorously evaluates the profound discrepancy in diagnostic efficiency between these traditional and modern screening paradigms within a precisely controlled clinical cohort.

Material and Methods

Study Design and Patient Selection

To objectively evaluate the diagnostic precision of cervical screening methods, a prospective, comparative clinical study was executed. The clinical trial concluded its diagnostic and analytical monitoring phase on March 28, 2026. The investigation included a rigidly controlled cohort of exactly 80 female patients (ages ranging from 25 to 55 years) who presented for routine gynecological screening or had a documented history of chronic cervical inflammation.

Inclusion Criteria: Women with an intact cervix, absence of visible macroscopic tumor masses, and no prior history of cervical conization or radiation therapy.

Exclusion Criteria: Acute purulent vaginitis (which severely distorts cytological results), active menstruation at the time of sampling, or confirmed pregnancy.

Diagnostic Protocol

Upon recruitment, the 80 patients were randomly and evenly divided into two diagnostic cohorts to simulate different screening environments:

1. **The Modern Method Group (n=40):** Screened using the modern "Co-testing" protocol. A single cervical sample was collected using a cytobrush and immediately suspended in a liquid preservative vial (Liquid-Based Cytology). The same vial was subjected to automated molecular testing for 14 high-risk HPV DNA genotypes (using PCR amplification) and microscopic

morphological evaluation. All patients in this group additionally underwent extended digital video colposcopy with acetic acid and Lugol's iodine application to map any micro-lesions.

2. **The Control Group (n=40):** Screened strictly using the conventional method. Samples were smeared directly onto a glass slide, fixed with a standard aerosol fixative, and sent for traditional Pap staining. Triage to colposcopy in this group occurred *only* if the initial Pap smear returned an abnormal result, mimicking standard low-resource clinical protocols.

Targeted punch biopsies and subsequent histopathological examination (the gold standard) were performed on any patient displaying abnormal colposcopic findings in either group to confirm the true diagnosis.

Statistical Analysis

Clinical and laboratory data were recorded in structured registries. Statistical analysis of screening metrics (Sensitivity, Specificity, Positive Predictive Value) was performed using Python data analysis libraries (pandas, numpy). Comparisons utilized Chi-square ($\chi 2$) tests for categorical diagnostic variables. A p-value of <0.05 was defined as indicating statistical significance.

Result and Discussion

Detection and Stratification of Cervical Pathologies

The fundamental goal of a screening program is to cast a wide, highly sensitive net to capture true pathology without overwhelming the system with false positives. The diagnostic phase of this study revealed massive discrepancies in detection capabilities.

Table 1

Detection Profile of Cervical Pathologies by Screening Modality

Histopathological Diagnosis (Gold Standard)	Modern Group (LBC + HPV DNA, n=40)	Control Group (Conventional Pap, n=40)	Total Cohort (n=80)
Normal / Reactive Changes only	12	22 (Many false negatives)	34
Background Lesions (Ectopy, Leukoplakia)	14	11	25
Low-Grade Precancer (CIN I / LSIL)	7	5	12
High-Grade Precancer (CIN II-III / HSIL)	7	2	9

Extensive Clinical Explanation of Table 1:

Table 1 illustrates the stark reality of relying on outdated diagnostic methods. The Gold Standard histopathology revealed the true incidence of disease in the cohorts. In the **Modern Group**, the combination of HPV DNA detection and Liquid-Based Cytology accurately identified 14 patients with significant background lesions and a critical 14 patients with true precancerous dysplasia (7 with CIN I, and 7 with severe CIN II/III).

In contrast, the **Control Group** utilizing the conventional Pap smear reported 22 patients as "Normal/Reactive." However, because this group lacked molecular HPV mapping and routine colposcopy, a significant portion of these "normal" results were actually false negatives. Most alarmingly, the conventional method only detected 2 cases of High-Grade Precancer (HSIL/CIN II-III). The remaining high-grade lesions in that cohort were missed entirely because the dysplastic cells were either obscured by mucus/blood on the glass slide or were simply not captured on the smear, leaving those women at severe risk of progressing to invasive carcinoma.

Diagnostic Efficiency Metrics

BG Pulse Journal USA
ISSN:1947-2536 http://www.bgpulseusa.com/index.php/bg
BG PULSE JOURNAL

To definitively quantify the performance of the two screening approaches, standard epidemiological metrics were calculated against the histopathological biopsies.

Table 2

Diagnostic Efficiency Metrics of the Screening Protocols

Diagnostic Metric	Modern Co-testing Protocol (LBC + HPV)	Conventional Protocol (Pap Smear Only)	Statistical Significance (p-value)
Sensitivity (Ability to detect true disease)	95.0%	61.5%	$p < 0.01$
Specificity (Ability to rule out healthy patients)	88.2%	76.4%	$p < 0.05$
Positive Predictive Value (PPV)	91.3%	66.6%	$p < 0.01$
False Negative Rate	5.0%	38.5%	$p < 0.001$

Extensive Clinical Explanation of Table 2:

Table 2 provides the mathematical proof of the modern protocol's superiority. The **Sensitivity** of the Modern Co-testing protocol reached an exceptional 95.0%. This means that if a patient actually has a precancerous lesion, the modern test will correctly flag it 95 times out of 100. The molecular presence of HPV DNA acts as a massive "red flag" for the cytopathologist, ensuring they scrutinize the cellular sample meticulously.


Conversely, the Conventional Pap smear yielded a dismal sensitivity of only 61.5%, paired with a devastating **False Negative Rate of 38.5%**. In a clinical setting, this means that nearly 4 out of 10 women who harbor dangerous precancerous cellular changes are told they are perfectly healthy and sent home, allowing the virus to silently drive the progression toward invasive cancer over the subsequent years. The Modern protocol essentially eliminates this risk, reducing false negatives to a mere 5.0%.

Data Visualization: True Detections vs. False Negatives

To visually synthesize the critical differences in diagnostic safety between the two cohorts, the following Python-generated visualization contrasts the successful detection of severe precancer against the dangerous rate of false negatives.

Diagram 1

BG Pulse Journal USA
ISSN:1947-2536 http://www.bgpulseusa.com/index.php/bg
BG PULSE JOURNAL



Extensive Explanation of the Diagrammatic Results:

The clustered bar chart elegantly summarizes the clinical safety profile of the two screening modalities evaluated in this trial.

The first cluster ("Accurate Detection of Precancer") highlights the sheer diagnostic power of the **Modern Protocol Group** (blue bars). By combining molecular HPV tracking with clean LBC preparations, the system successfully identified 14 actual cases of CIN. The **Conventional Protocol Group** (red bars) managed to find only exactly half of that amount (7 cases), missing the others entirely.

The most clinically significant cluster is the center one: "Dangerous Missed Lesions (False Negatives)." The Conventional Protocol resulted in 8 patients being falsely cleared—patients who, unbeknownst to them, harbored actively developing dysplasia. In the Modern Protocol cohort, this catastrophic failure was virtually eliminated, with only 1 patient falling into the false negative category. This visualization clearly proves that relying on human eyes and a conventional smear on a glass slide is no longer medically defensible when molecular tools can prevent cancer progression with near-absolute certainty.

Conclusion

Cervical cancer is a unique oncological entity in that its entire progression is mapped, understood, and entirely preventable. However, secondary prevention is only as effective as the diagnostic tools employed. The comprehensive findings of this clinical trial—concluding on March 28, 2026, with a rigorously controlled cohort of 80 patients—demonstrate unequivocally that traditional Conventional Pap smears are inadequate for modern oncological safety.

With a false-negative rate approaching 40%, the traditional method allows a vast reservoir of high-grade precancerous lesions (CIN II/III) to remain undetected within the population. Conversely, the modern diagnostic paradigm—Liquid-Based Cytology combined with High-Risk HPV DNA molecular testing—achieves an exceptional sensitivity of 95.0%. By detecting the viral molecular trigger and providing a pristine cellular sample for morphological evaluation, modern co-testing ensures that background diseases and precancerous lesions are identified and treated years before invasive malignancy can take hold. Transitioning national screening programs to this

molecular paradigm is the singular most effective step toward the total eradication of cervical cancer.

References

1. Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007). Human papillomavirus and cervical cancer. *The Lancet*, *370*(9590), 890-907.
2. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., ... & Muñoz, N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *The Journal of Pathology*, *189*(1), 12-19.
3. Doorbar, J., Egawa, N., Griffin, H., Kranjec, C., & Murakami, I. (2015). Human papillomavirus molecular biology and disease association. *Reviews in Medical Virology*, *25*(S1), 2-23.
4. Sawaya, G. F., Smith-McCune, K., & Kuppermann, M. (2019). Cervical cancer screening. *Obstetrics & Gynecology*, *133*(5), 983-991.
5. Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., & Matchar, D. B. (2000). Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. *Annals of Internal Medicine*, *132*(10), 810-819.
6. Arbyn, M., Bergeron, C., Klinkhamer, P., Martin-Hirsch, P., Siebers, A. G., & Bulten, J. (2008). Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. *Obstetrics & Gynecology*, *111*(1), 167-177.
7. Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J., Arbyn, M., ... & Meijer, C. J. (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. *The Lancet*, *383*(9916), 524-532.